Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.
Back to dashboard
Company Information
About this company
Key people
Rodney S. Markin
Independent Chairman of the Board
Renee P. Tannenbaum
Independent Director
Lale White
Independent Director
Mani Mohindru
President, Chief Executive Officer, Director
Joshua B. Muntner
Chief Financial Officer
Ajay Aggarwal
Chief Operating Officer
Brigitte Lindsay
Chief Accounting Officer
Tod Smeal
Chief Scientific Officer
Roger Sidhu
Chief Medical Officer
James O. Armitage
Independent Director
Gary William Pace
Independent Director
Click to see more
Key facts
- Shares in issue77.80m
- EPICCRDF
- ISINUS14147L1089
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$70.10m
- Employees31
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.